Login / Signup

A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.

Matthew C BakerAudra HoromanskiYiwen WangLiu YuhanShima ParsafarRobert FairchildJoshua J MooneyRishi RajRonald WittelesMark C Genovese
Published in: Rheumatology (Oxford, England) (2023)
ClinicalTrials.gov Identifier: NCT04008069.
Keyphrases
  • placebo controlled
  • phase iii
  • double blind
  • phase ii
  • study protocol
  • clinical trial
  • open label
  • phase ii study
  • randomized controlled trial
  • replacement therapy